US 2024/0181037 A1Published application

Immunogenic compositions

AssigneesGlaxosmithkline Biologicals SA, CureVac AG

InventorsHans Wolfgang GROßE, Edith JASNY, Janine MÜHE, Ventzislav Bojidarov VASSILEV, Clarisse LORIN, Nadia OUAKED, Corey MALLETT, Ronan ROUXEL, Normand BLAIS

Life of this patent

Estimating the term…

Abstract

The present invention relates to carrier-formulated mRNA comprising at least one coding sequence encoding an influenza HA stem polypeptide, and to related aspects.

Claims20

Dependent claims

1-116. (canceled)

Dependencies are inferred from the claim text.

Facts

Application: 18/283,601Filed 25 Mar 2022
Priority: 26 Mar 2021
Published: 6 Jun 2024
Term ends: Not estimatedThe source records don’t support an estimate.

Classification23 codes

A61K 39/145
Viral antigens: orthomyxoviridae, e.g. influenza virus
A61K 9/0019
Galenical forms characterised by the site of application: injectable compositions; Intramuscular, intravenous, arterial, subcutaneous…
A61K 9/5123
Excipients; Inactive ingredients: organic compounds, e.g. fats, sugars
A61K 31/7105
Compounds having three or more nucleosides or nucleotides: natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine,…

Family

Application63/166,539Us provisional application · filed 26 Mar 2021
US 2024/0181037 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key

patentgrep

Loading patent…

patentgrepSearch patents

Back to results